Senate Bill 865 Printer's Number 966

PENNSYLVANIA, June 18 - as part of the urine drug screening panel.

(b) Reporting.--

(1) If the urine drug screening conducted in accordance

with subsection (a) detects fentanyl, medetomidine or

xylazine, the emergency department shall report the test

results, which shall be deidentified, to the department and

shall provide informational materials under section 5903(a)

(2) (relating to xylazine awareness education) or 5903.1(a)

(2) (relating to medetomidine awareness education).

(2) The department shall determine the manner of

submission of test results.

(3) Reporting for fentanyl, medetomidine and xylazine

shall occur when results meet a screening threshold set by

the department.

* * *

(d) Definitions.--As used in this section, the following

words and phrases shall have the meanings given to them in this

subsection unless the context clearly indicates otherwise:

* * *

"Urine drug screening." A chemical analysis intended to test

a patient for the presence of a controlled substance,

medetomidine or xylazine.

Section 2. Title 35 is amended by adding a section to read:

§ 5903.1. Medetomidine awareness education.

(a) Powers and duties.--The Department of Drug and Alcohol

Programs, in consultation with the Department of Health and the

Department of Agriculture, shall have the power and its duty

shall be to:

(1) Enter into partnerships with health care providers,

including physicians and veterinarians, and community-based

20250SB0865PN0966 - 2 -

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30